Spots Global Cancer Trial Database for aromasin
Every month we try and update this database with for aromasin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Exemestane-RAD001-Metformin | NCT01627067 | Breast Cancer | Everolimus Exemestane Metformin | 18 Years - | M.D. Anderson Cancer Center | |
| Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant | NCT00919399 | Breast Neoplasm... | Exemestane tamoxifen | 60 Years - | Institut Claudius Regaud | |
| Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer | NCT01239745 | Breast Neoplasm... | Aromasin | - | Pfizer | |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| The Impact of Obesity and Obesity Treatments on Breast Cancer | NCT00933309 | Breast Cancer | Exemestane Avandamet | 18 Years - | M.D. Anderson Cancer Center | |
| A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients | NCT01305239 | Breast Cancer | Aromasin | 45 Years - | Pfizer | |
| An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin | NCT00776659 | Breast Neoplasm... | Aromasin | 18 Years - 75 Years | Pfizer | |
| A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer | NCT01121549 | Invasive Early ... | Aromasin | - | Pfizer | |
| An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin | NCT00776659 | Breast Neoplasm... | Aromasin | 18 Years - 75 Years | Pfizer | |
| A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer | NCT01121549 | Invasive Early ... | Aromasin | - | Pfizer | |
| Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer | NCT01047358 | Breast Cancer | Aromasin Aromasin | 18 Years - | Pfizer | |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients | NCT01305239 | Breast Cancer | Aromasin | 45 Years - | Pfizer | |
| Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant | NCT00919399 | Breast Neoplasm... | Exemestane tamoxifen | 60 Years - | Institut Claudius Regaud | |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
